Shanghai Junshi Bioscience
Last updated Jul 7, 2026
Evidence Sources
3
Competitive Findings
0
Portfolio Developments
0
Regulatory Precedents
7
Clinical Programs
0
Confidence Coverage
71%
Audit
- Competitor findings: 0
- Portfolio developments: 0
- Self-competition findings removed: 0
- Unknown ownership findings removed: 0
Executive Summary
Material intelligence activity detected across:
- Oncology
- Nasopharyngeal Carcinoma
- NSCLC
- HCC
Highest priority development: FDA approves belzutifan with pembrolizumab for adjuvant treatment of renal cell carcinoma
Regulatory precedent
Why this matters: provides agency context on approval that may shape timing or evidence expectations for Shanghai Junshi Bioscience.
Competitive pressure: Low
Portfolio impact: High
Evidence coverage: 71%
Active Signals
3
Investigate Priority
0
Opportunity Score
73
Buyer Quality
6 · Emerging
Recent Signals
Latest intelligence events linked to this organization.
- MonitorJul 7, 2026Score 27Phase III Trial of Toripalimab and Lenvatinib for Advanced HCC Initiated
Oncology · HCC
- MonitorJul 19, 2026Score 23Phase I Study of JS001sc in Advanced Nasopharyngeal Carcinoma Shows Focus on Safety and Tolerability
Oncology · Nasopharyngeal Carcinoma
- MonitorJul 8, 2026Score 23Phase II Study of JS212 Plus JS111 in EGFR-Mutant NSCLC Initiated by Shanghai Junshi Bioscience
Oncology · NSCLC
Related Assets
Portfolio asset pages with evidence-based assessments.
No linked asset pages are available yet.
Portfolio Development
Owned-asset pipeline events — Phase III readouts, approvals, label expansions, and deals. Not classified as competitive threats.
No portfolio development items are linked to this company yet.
Competitive Intelligence Findings
Competitiva findings with evidence, reasoning, and confidence calibration.
No Competitiva findings are linked to this company yet.
Regulatory Developments
Regunera precedents with source attribution and confidence disclosure.
- FDA approves belzutifan with pembrolizumab for adjuvant treatment of renal cell carcinomaModerate Confidence · 65%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera - FDA approves gedatolisib with fulvestrant, with or without palbociclib, for HR-positive, HER2-negative locally advanced or metastatic breast cancerModerate Confidence · 65%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera - FDA grants traditional approval to selpercatinib for locally advanced or metastatic RET fusion-positive solid tumorsModerate Confidence · 65%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera - IND Application Reporting: IND Safety ReportsModerate Confidence · 83%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera
Clinical Developments
Pipeline activity with auditable evidence and uncertainty disclosure.
No clinical developments are linked yet.
Capital Markets
SEC filings, IPO activity, and capital markets events from the Business Intelligence Layer.
No capital markets intelligence is available yet.
Financing History
Venture funding, follow-on offerings, PIPE financings, and debt financing.
No financing history is available yet.
Licensing & Partnerships
Licensing agreements, strategic partnerships, and distribution deals.
No licensing or partnership activity is available yet.
M&A Activity
Acquisitions, mergers, and divestitures.
No M&A activity is available yet.
Investor Activity
Earnings releases, investor presentations, and conference appearances.
No investor activity is available yet.
Executive Changes
CEO appointments, board changes, and leadership restructuring.
No executive changes are available yet.
Business Timeline
Chronological business intelligence events across financing, licensing, M&A, and commercial strategy.
No business timeline events are available yet.
Strategic Signals
Higher-order strategic intelligence fused from regulatory, scientific, business, and competitive events. Signals answer what it means — not just what happened.
Strategic signals will appear once sufficient event convergence is detected.
Investigate-Priority Items
Signals flagged for investigation or escalation — highest urgency for portfolio review.
No investigate-priority signals are active for this company.
Humanexa Agent Questions
Suggested prompts to explore this organization's intelligence profile. Open a linked signal to ask the agent.
- What are the most material competitive threats to Shanghai Junshi Bioscience right now?
- Which regulatory precedents should Shanghai Junshi Bioscience monitor in Oncology and Nasopharyngeal Carcinoma?
- Which pipeline programs should Shanghai Junshi Bioscience prioritize for competitive review?
- What signals require immediate investigation for Shanghai Junshi Bioscience?
- Summarize the strategic implications of recent developments for Shanghai Junshi Bioscience.
- Where is the greatest uncertainty in Shanghai Junshi Bioscience's competitive positioning?